Proteome Sciences plc (AIM:PRM)

Market Cap	5.61M -41.7%
Revenue (ttm)	3.76M -23.1%
Net Income	-3.06M
EPS	-0.01
Shares Out	350.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	233,157
Open	1.600
Previous Close	1.600
Day's Range	1.600 - 1.639
52-Week Range	1.200 - 4.400
Beta	0.17
Analysts	n/a
Price Target	6.00 (+275.0%)
Earnings Date	Jun 25, 2026

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling p...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1993
• Employees: 32
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PRM

Financial Performance

In 2025, Proteome Sciences's revenue was 3.76 million, a decrease of -23.14% compared to the previous year's 4.89 million. Losses were -3.06 million, -10.13% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 17, 2026

Data Sources Report a data error